Selected one way sensitivity analysis: incremental cost per LYS (£) v BSC
| GEM | GEM+ CDDP | VNB | VNB+ CDDP | PAX | PAX (135)† +CDDP | PAX (175)† +CDDP | PAX (250)† +CDDP | DOC | DOC (2L) | |
|---|---|---|---|---|---|---|---|---|---|---|
| BSC=best supportive care; GEM=gemcitabine; VNB=vinorelbine; PAX=paclitaxel; DOC=docetaxel; CDDP=cisplatin; LYS=life years saved; 2L=second line treatment; SESLS=South-east Scotland Lung Study; D=dominant strategy v BSC. It is not appropriate to show a figure when a strategy is dominant; X=dominated, higher cost and lower survival than BSC. | ||||||||||
| Data in italics were provided by industry. | ||||||||||
| *Cisplatin components not discounted; †dose in mg/m2. | ||||||||||
| Baseline | 5690 | 10041 | 4091 | 5206 | 46610 | 8537 | 14124 | 12104 | 26707 | 17546 |
| 3 cycles: VNB,GEM,DOC; 4 PAX | 5690 | 5145 | 4091 | 5206 | 31957 | 5198 | 9398 | 12104 | 26707 | 17546 |
| 60% prob. half course, 40% full course | D | 2478 | D | 2808 | 16461 | 2179 | 4879 | 7204 | 7952 | 569 |
| VNB cycle: 21 days/3 administrations | NA | NA | D | 1982 | NA | NA | NA | NA | NA | NA |
| VNB cycle: 21 days/2 administrations | NA | NA | D | D | NA | NA | NA | NA | NA | NA |
| 25% discount on BNF | 939 | 7079 | 564 | 3208 | 30469 | 5392 | 9416 | 8021 | 11078 | 3398 |
| 50% discount on BNF | D | 4116 | D | 1209 | 14327 | 2248 | 4708 | 3937 | D | D |
| Anti-emetics £150 | 6771 | 10547 | 5080 | 5767 | 48023 | 8970 | 14627 | 12482 | 29066 | 20119 |
| Bethelot's mean survival15 | 1925 | NA | 2216 | 3167 | NA | 5196 | NA | 8429 | NA | NA |
| Berthelot's QoL utilities15 | 5538 | NA | 5105 | 7290 | NA | 11296 | NA | 16358 | NA | NA |
| Best survival | 2903 | 9253 | 3442 | 3833 | 38008 | NA | 11314 | NA | 7375 | 5425 |
| Worst survival | 20458 | 12484 | 5895 | 11430 | 163647 | NA | 17636 | NA | X | 46680 |
| SESLS BSC cost (£3572) | 4034 | 9267 | 2576 | 4348 | 44447 | 7875 | 13352 | 11525 | 23093 | 13605 |
| Lower BSC estimate (£2200) | 13923 | 13892 | 11622 | 9473 | 57364 | 11830 | 17957 | 14982 | 44670 | 37134 |
| Best cycles | D | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Worst cycles | 23089 | 14938 | 11677 | 10467 | NA | NA | 18849 | NA | NA | NA |
| OP administration | NA | 8255 | NA | 3722 | 43058 | NA | NA | NA | 23146 | 13664 |
| Reduced dose (if <20% of vial used) | NA | NA | 1618 | 3805 | NA | NA | NA | NA | NA | NA |